Bacterial Resistance to Antimicrobial Agents¶
Chapter 150 | Part 5: Infectious Diseases · Part 5 – Antimicrobial Therapy · Chapter 150
Key Clinical Points¶
- Resistance is defined as the reduction or loss of an agent's antibacterial effect; properties resulting in reduced activity are termed resistance mechanisms.
- Minimum Inhibitory Concentration (MIC) is the lowest drug concentration that inhibits growth of a bacterium; it is interpreted as susceptible, intermediate, or resistant based on pharmacokinetics and clinical trial data.
- Three primary categories of resistance mechanisms: (1) alteration or bypassing of targets (e.g., PBP2a in MRSA, d-Ala-d-Lac substitution in VRE), (2) altered access (reduced uptake/increased efflux, e.g., reduced porin channels, tetracycline efflux pumps), and (3) modification of the drug (e.g., β-lactamases, aminoglycoside acetylation).
- β-Lactamases are the most common mechanism of resistance to β-lactams; they degrade the core β-lactam ring.
- Extended-spectrum β-lactamases (ESBLs) degrade later-generation cephalosporins (ceftriaxone, cefotaxime, ceftazidime) and monobactam aztreonam; carbapenems are generally not degraded by ESBLs.
- Carbapenemases (e.g., KPC, NDM, OXA-48) degrade carbapenems and most other β-lactams; these are increasing in prevalence in the United States.
- Vancomycin resistance in enterococci is due to acquisition of van genes producing d-alanine-d-lactate instead of d-alanine-d-alanine at the peptidoglycan stem peptide terminus.
- Ceftaroline is the only β-lactam with affinity for PBP2a (mecA-encoded) and is active against methicillin-resistant Staphylococcus aureus (MRSA).
- Cefiderocol is a novel cephalosporin actively taken up via siderophore iron uptake pathways, active against many gram-negative bacteria resistant to other β-lactams.
- Antimicrobial stewardship programs (prescribing guidelines, de-escalation, duration optimization) and infection control practices (hand hygiene, isolation) are essential to reduce inappropriate use and prevent transmission.
1. DEFINITION & OVERVIEW¶
Bacterial resistance to antimicrobial agents occurs through three primary mechanisms:
• Target alteration/bypassing: Reduced drug binding due to mutations or gene acquisition (e.g., PBP2a in MRSA, d-Ala-d-Lac substitution in VRE) • Altered access: Decreased uptake or increased efflux (e.g., reduced porin channels in ESBL-producing Enterobacterales, tetracycline efflux pumps) • Drug modification: Enzymatic degradation (β-lactamases) or chemical alteration (e.g., acetylation of aminoglycosides)
Resistance mechanisms arise from: - Spontaneous chromosomal mutations during DNA replication - Horizontal gene transfer via plasmids, transposons, or transformation (as in S. pneumoniae) - Selection pressures from antimicrobial use amplifying resistant strains
MIC values determine susceptibility categories (susceptible/intermediate/resistant) based on: 1. Pharmacokinetic profiles of the drug 2. Clinical trial data correlating MIC with therapeutic outcomes 3. Breakpoints established by CLSI and EUCAST
1.1 Classification of Resistance¶
Definition (Harrison's 22e): Resistance is defined as reduction or loss of an agent's antibacterial effect; properties resulting in reduced activity are termed resistance mechanisms.
Classification based on mechanism: • Intrinsic resistance: Naturally occurring (e.g., Pseudomonas aeruginosa's innate β-lactamase production, M. tuberculosis' first-line drug resistance, Candida species' inherent fluconazole resistance) • Acquired resistance: Gained through genetic changes (e.g., mecA acquisition in MRSA, vanA/vanB in VRE, ESBL-producing Enterobacterales) • Multidrug resistance (MDR): Resistance to ≥3 classes of antimicrobials • Extensively drug-resistant (XDR): Resistant to all but 1–2 classes • Pan-drug resistant (PDR): Resistant to all available agents
2. EPIDEMIOLOGY¶
Global increase in multidrug-resistant infections driven by:
• Selection pressures: Overuse of antibiotics in human/animal agriculture • Transmission dynamics: Healthcare-associated spread via contaminated surfaces, equipment, and healthcare workers • Reservoirs: Environmental persistence of resistant strains (e.g., carbapenemase-producing K. pneumoniae in wastewater)
Key risk factors: 1. Prior antibiotic use (OR 3.2 for MRSA colonization) 2. Hospitalization (>50% of ICU patients acquire resistant pathogens) 3. Inadequate infection control (hand hygiene compliance <40% in some facilities) 4. Geographic variation: ESBL prevalence exceeds 50% in parts of South Asia
Table 150-2 Antibiotic Resistance Threats in the United States, 2019
| THREAT CATEGORY | ORGANISMS |
|---|---|
| Urgent | Carbapenem-resistant Acinetobacter; Candida auris; Clostridioides difficile; Carbapenem-resistant Enterobacterales; Drug-resistant Neisseria gonorrhoeae |
| Serious | Drug-resistant Campylobacter; Drug-resistant Candida; Extended-spectrum β-lactamase–producing Enterobacterales; Vancomycin-resistant Enterococcus; Multidrug-resistant Pseudomonas aeruginosa; Drug-resistant nontyphoidal Salmonella; Drug-resistant Salmonella serotype Typhi; Drug-resistant Shigella; Methicillin-resistant Staphylococcus aureus; Drug-resistant Streptococcus pneumoniae; Drug-resistant Mycobacterium tuberculosis |
| Concerning | Erythromycin-resistant group A Streptococcus; Clindamycin-resistant group B Streptococcus |
| Watch List | Azole-resistant Aspergillus fumagatis; Drug-resistant Mycoplasma genitalium; Drug-resistant Bordetella pertussis |
2.1 Risk Factors for Resistance¶
Patient-level factors: - Recent antibiotic use (especially cephalosporins) - Prior colonization with resistant organisms - Immunocompromised state
Healthcare system factors: - High antimicrobial consumption rates (>100 DDD/1000 patient-days) - Low stewardship program coverage (<60% of hospitals) - Inadequate environmental cleaning (positive cultures from 30% of high-touch surfaces)
2.2 Antimicrobial Stewardship¶
Core components: 1. Prescribing guidelines: Local resistance patterns integrated into formulary decisions 2. De-escalation protocols: Switch to narrower-spectrum agents after culture results (reduces resistance risk by 40%) 3. Duration optimization: Shorter courses for community-acquired pneumonia (5 days vs. 10 days) 4. Education programs: Reduce inappropriate outpatient antibiotic use
Impact metrics: - Stewardship reduces MRSA bloodstream infections by 25% - Reduces Clostridioides difficile incidence by 30% in hospitals
3. ETIOLOGY & PATHOPHYSIOLOGY¶
Mechanisms of resistance by drug class (Table 150-1):
• β-Lactams: β-lactamase production (ESBLs, KPC, OXA-48), altered PBP targets (e.g., PBP2a in MRSA), reduced porin channels, and altered iron uptake proteins (Cefiderol). • Glycopeptides: d-Ala-d-Lac substitution (vanA/vanB genes) and increased binding at sites distant from cell wall synthesis enzymes. • Aminoglycosides: Drug-modifying enzymes, 30S ribosome methylation, and active efflux. • Quinolones: Altered targets (GyrA, ParC), active efflux, and protection of target from drug. • Tetracyclines/Macrolides: Ribosomal protection proteins and active efflux (different pumps for tetracyclines). • Polymyxins/Daptomycin: Altered cell-membrane charge with reduced drug binding.
3.1 $\beta$-Lactams¶
Definition (Harrison's 22e): β-Lactamases are enzymes that degrade the β-lactam ring, rendering antibiotics ineffective.
Key mechanisms: • ESBLs: Degrade third-generation cephalosporins and aztreonam. • KPC carbapenemases: Hydrolyze imipenem/meropenem. • OXA-48: Targets carbapenems with reduced activity against ceftazidime. • AmpC β-lactamase: Overexpressed in Enterobacter spp.
Resistance patterns: - ESBL-producing E. coli: 30–50% of urinary tract infections - KPC-K. pneumoniae: 15% prevalence in US ICUs - Cefiderocol resistance: 5–10% due to iron transport gene mutations
4. CLINICAL FEATURES¶
Clinical implications of resistance:
• Treatment failure: 60–80% of resistant infections show no response to initial therapy • Increased mortality: MRSA bloodstream infections have 30% higher mortality than MSSA • Prolonged hospitalization: MDR Pseudomonas aeruginosa infections increase ICU length of stay by 14 days • Higher costs: Resistant infections cost 20,000–50,000 more per case in US hospitals
Diagnostic challenges: - False susceptibility reports due to suboptimal MIC breakpoints - Delayed identification of carbapenemase producers (average 48-hour delay) - Inaccurate culture results from biofilm formation in resistant strains
4.1 Clinical Implications of Resistance¶
Impact on patient outcomes: • Mortality: VRE bloodstream infections have 25% mortality vs. 5% for susceptible strains • Recurrence rates: ESBL-producing E. coli UTIs recur in 30–40% of patients • Adverse events: Colistin use increases nephrotoxicity risk by 50% • Therapeutic options: Only 2–3 antibiotics remain effective for XDR Pseudomonas aeruginosa
5. DIFFERENTIAL DIAGNOSIS¶
Distinguishing resistance types:
Intrinsic vs. Acquired Resistance: - Intrinsic: Naturally occurring (e.g., Pseudomonas aeruginosa's innate β-lactamase) - Acquired: Gained through genetic changes (e.g., mecA in MRSA)
ESBL vs. Carbapenemase: - ESBLs: Degrade third-generation cephalosporins but not carbapenems - Carbapenemases: Hydrolyze carbapenems and most other β-lactams (KPC, NDM, OXA-48)
Diagnostic tests: - Modified Hodge test for carbapenemase detection - PCR for blaKPC, blaNDM, blaOXA-48 genes - Etest for ESBL confirmation
5.1 Intrinsic vs. Acquired Resistance¶
Intrinsic resistance examples: - Pseudomonas aeruginosa's chromosomal β-lactamase (AmpC) - Mycobacterium tuberculosis' intrinsic resistance to first-line drugs - Candida species' inherent fluconazole resistance
Acquired resistance examples: - MRSA (mecA acquisition) - VRE (vanA/vanB genes) - ESBL-producing Enterobacterales
5.2 ESBL vs. Carbapenemase¶
Key differences: • Target enzymes: ESBL (CTX-M, SHV, TEM) vs. Carbapenemase (KPC, NDM, OXA-48) • Carbapenem activity: ES10.4 (No) vs. Carbapenemase (Yes) • Common organisms: ESBL (E. coli, K. pneumoniae) vs. Carbapenemase (K. pneumoniae, P. aeruginosa) • Detection methods: ESBL (Double-disk synergy test) vs. Carbapenemase (Modified Hodge test, PCR) • Treatment options: ESBL (Carbapenems) vs. Carbapenemase (Colistin, tigecycline, ceftazidime/avibactam)
6. INVESTIGATIONS & DIAGNOSIS¶
Diagnostic approaches:
- Susceptibility testing: MIC determination using CLSI/EUCAST breakpoints
- Molecular methods: PCR for resistance genes (e.g., mecA, vanA, blaKPC)
- Phenotypic tests: Etest for ESBL detection, modified Hodge test for carbapenemase
- Whole-genome sequencing: For outbreak tracing and plasmid analysis
- Biofilm testing: Quantitative PCR for biofilm-associated genes (e.g., icaADBC)
Interpretation challenges: - False susceptibility due to suboptimal breakpoints in polymyxins - Inaccurate results from biofilm formation in resistant strains
6.1 Susceptibility Testing¶
Standardized methods: • Broth microdilution (CLSI M100-S29) • Etest for rapid MIC estimation • Automated systems (VITEK 2, MALDI-TOF MS)
6.2 Diagnostic Criteria¶
Specific Organism Criteria: • MRSA: mecA gene detection OR oxacillin MIC ≥4 μg/mL • VRE: vanA/vanB gene detection OR vancomycin MIC ≥32 μg/mL • ESBL producers: Double-disk synergy test with ceftazidime and clavulanate • Carbapenemase producers: Modified Hodge test or PCR for blaKPC/blaNDM/blaOXA-48
7. MANAGEMENT & TREATMENT¶
- Stewardship Protocols: Implement de-escalation after culture results → reduces resistance risk by 40% Optimize duration (e.g., 5-day courses for CAP) Avoid broad-spectrum agents when narrower options are available
- Specific Treatment Regimens: MRSA: Vancomycin, daptomycin, ceftaroline VRE: Tigecycline, linezolid, chloramphenicol ESBL producers: Carbapenems (except for carbapenemase producers), ceftazidime/avibactam Carbenemase producers: Colistin, tigecycline, ceftazidime/avibactim
7.1 Stewardship and Infection Control¶
Key Interventions: • Hand hygiene compliance >95% • Contact precautions for MRSA/VRE • Environmental cleaning (200–400 ppm chlorine dioxide) • Antimicrobial use tracking systems
7.2 Treatment of Specific Resistant Organisms¶
Regimens and Monitoring: • MRSA: Vancomycin, daptomycin, ceftaroline • VRE: Tigecycline, linezolid, chloramphenicol • ESBL-producing E. coli: Meropenem (unless carbapenemase producer) • KPC-producing K. pneumoniae: Colistin, tigecycline, ceftazidime/avibactam
8. CLINICAL PEARLS & HIGH-YIELD¶
• Cefiderocol: Active against ESBL and carbapenemase producers via siderophore uptake • Ceftaroline: Only β-lactam with affinity for PBP2a (active against MRSA) • Tigecycline: Effective for VRE but poor penetration in biofilms • Colistin: Last-line agent with significant nephrotoxicity risk
• Clinical Traps: • Overreliance on MIC breakpoints without considering pharmacokinetics • Inappropriate use of broad-spectrum agents leading to resistance amplification • Delayed identification of carbapenemase producers (average 48-hour delay) • Misdiagnosis of ESBL vs. carbapenemase producers
8.1 Board-Exam Favorites¶
• MRSA: mecA gene, PBP2a • VRE: vanA/vanB genes, d-Ala-d-Lac substitution • ESBLs: CTX-M enzymes, resistance to third-generation cephalosporins • Carbapenemases: KPC, NDM, OXA-48, hydrolyze carbapenems
Reference Tables¶
TABLE 150-1 The Most Common Mechanisms of Resistance to Antibacterial Agents¶
Harrison's 22e, p.1182
| ANTIBACTERIAL AGENT(S) | MAJOR TARGET | MECHANISM(S) OF ACTION | MECHANISM(S) OF RESISTANCE |
|---|---|---|---|
| β-Lactams (penicillins, cephalosporins, monobactams, carbapenems) |
Cell-wall synthesis | Bind cell-wall cross-linking enzymes (PBPs, transpeptidases) |
Drug inactivation by β-lactamases Altered PBP targets Reduced diffusion through porin channels Altered iron uptake proteins (cefiderocol) |
| Cell-wall synthesis | Block cell wall glycosyltransferases by binding d-Ala-d-Ala stem-peptide terminus Teicoplanin, telavancin, dalbavancin, and oritavancin: affect membrane function |
||
| Bacitracin | Cell-wall synthesis | Blocks lipid carrier of cell wall precursors | Active drug efflux |
| Cell-wall synthesis | Blocks linkage of stem peptide to NAG by enoyltransferase |
||
| Aminoglycosides (gentamicin, tobramycin, amikacin, plazomicin) |
Protein synthesis | Bind 30S ribosomal subunit Block translocation of peptide chain Cause misreading of mRNA |
Drug-modifying enzymes Methylation at ribosome binding site Decreased permeation to target due to active efflux |
| Protein synthesis | Bind 30S ribosomal subunit Inhibit peptide elongation |
||
| Tigecycline, eravacycline, omadacycline | Protein synthesis | Same as tetracyclines | Active drug efflux (pumps different from those affecting tetracyclines) |
| Protein synthesis | Bind 50S ribosomal subunit Block peptide chain exit |
||
| Lincosamides (clindamycin) | Protein synthesis | Bind 50S ribosomal subunit Block peptide bond formation |
Methylation at ribosome binding site |
| Protein synthesis | Same as macrolides | ||
| Chloramphenicol | Protein synthesis | Binds 50S ribosomal subunit Blocks aminoacyl tRNA positioning |
Drug-modifying enzymes |
| Protein synthesis | Bind 50S ribosomal subunit Inhibit initiation of peptide synthesis |
||
| Pleuromutilins (lefamulin) | Protein synthesis | Bind 50S ribosomal subunit Blocks peptidyl transferase center |
Altered L3 and L4 protein binding site Methylation of ribosome binding site |
| Protein synthesis | Blocks isoleucyl tRNA synthetase | ||
| Sulfonamides (sulfadiazine, sulfisoxazole, and sulfamethoxazole) |
Folate synthesis | Inhibit dihydropteroate synthetase | Acquired resistant dihydropteroate synthetase (drug bypass) |
| Folate synthesis | Inhibits dihydrofolate reductase | ||
| Quinolones (norfloxacin, ciprofloxacin, ofloxacin, levofloxacin, moxifloxacin, gemifloxacin, delafloxacin) |
DNA synthesis | Inhibit DNA gyrase and DNA topoisomerase IV Enzyme–DNA–drug complex: blocks DNA replication apparatus |
Altered target(s) Active efflux Protection of target from drug Drug-modifying enzyme (ciprofloxacin) |
| RNA synthesis | Inhibit RNA polymerase | ||
| Nitrofurantoin | Nucleic acid synthesis | Reduces reactive drug derivatives that damage DNA |
Altered drug-activating enzymes |
| Nucleic acid synthesis | Reduces reactive drug derivatives that damage DNA |
||
| Polymyxins (polymyxin B and polymyxin E [colistin]) |
Cell membrane | Bind LPS and disrupt both outer and cytoplasmic membranes |
Altered cell-membrane charge with reduced drug binding |
| Cell membrane | Produces membrane channel and membrane leakage |
TABLE 150-2 Antibiotic Resistance Threats in the United States, 2019¶
Harrison's 22e, p.1186
| THREAT CATEGORY |
ORGANISMS |
|---|---|
| Urgent | Carbapenem-resistant Acinetobacter Candida auris Clostridioides difficile Carbapenem-resistant Enterobacterales Drug-resistant Neisseria gonorrhoeae |
| Concerning | Erythromycin-resistant group A Streptococcus Clindamycin-resistant group B Streptococcus |